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Abstract
The association of posttraumatic stress disorder (PTSD) with cardiovascular disease risk may be
mediated by inflammation. Our objective was to examine the association between PTSD and
measures of inflammation and to determine whether these associations are due to shared familial
or genetic factors. We measured lifetime history of PTSD using the Structured Clinical Interview
for DSM-IV in 238 male middle-aged military veteran twin pairs (476 individuals), selected from
the Vietnam Era Twins Registry, who were free of cardiovascular disease at baseline. We assessed
inflammation using levels of high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6),
fibrinogen, white blood cells, vascular cell adhesion molecule-1, and intercellular adhesion
molecule-1 (ICAM-1). Geometric mean levels and percent differences by PTSD were obtained
from mixed-model linear regression analyses with adjustment for potential confounders. Within-
pair analysis was conducted to adjust for shared family environment and genetics (monozygotic
pairs). Overall, 12.4% of participants had a lifetime history of PTSD. Adjusted mean levels of
hsCRP and ICAM-1 were significantly higher among those with vs. without PTSD [hsCRP: 1.75
vs. 1.31 mg/l (33% difference); ICAM-1: 319 vs. 293 ng/ml (9% difference)]. Adjustment for
depression rendered the association of PTSD with hsCRP non-statistically significant. For IL-6, no
consistent association was seen. Within-pair analysis produced associations that were similar in
direction for all three markers but lesser in magnitude for hsCRP and IL-6. There was no evidence
of interaction by zygosity. Elevated hsCRP and ICAM-1 are associated with PTSD, and these
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associations may be confounded by shared non-genetic, antecedent familial and environmental
factors.
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Introduction
Posttraumatic stress disorder (PTSD), a disabling anxiety disorder that is secondary to
severe psychological stress, is common among military veterans with combat exposure
(Friedman et al., 1994). The lifetime prevalence of PTSD is 15–19% in Vietnam veterans
(Dohrenwend et al., 2006), and it is even higher among those who served in the recent Iraq
and Afghanistan conflicts (Hoge et al., 2004). PTSD is also common in the general
population, with a lifetime prevalence of 10–12% in women and 5–6% in men (Kessler et
al., 1994, Yehuda, 2002b). Increasing evidence points to PTSD as risk factor for the
development of atherosclerotic cardiovascular disease (Bedi and Arora, 2007, Boscarino,
2008, Player and Peterson, 2011, Kubzansky and Koenen, 2009, Coughlin, 2011). While the
proposed mechanisms for this association between PTSD and cardiovascular disease remain
primarily speculative (Boscarino, 2011), inflammation may play a role; the inflammatory
process is central to the development of atherosclerosis (Libby, 2006, Libby and Theroux,
2005, Rozanski et al., 1999) and the stress response may trigger an inflammatory response
(Song et al., 1999, Bierhaus et al., 2003). The establishment of an association between
PTSD and inflammatory processes might provide a target for intervention and possibly
prevent subsequent cardiovascular morbidity and mortality in those with PTSD.
Thus far, the evidence for an association of PTSD with inflammation is mostly from small
studies (n=15–30) in populations with different PTSD etiologies. For example, PTSD was
associated with higher levels of the pro-inflammatory markers C-reactive protein (CRP) and
interleukin 6 (IL-6) in some studies (Spitzer et al., 2010, von Kanel et al., 2010b, Sutherland
et al., 2003, Tucker et al., 2010, Gill et al., 2008), but this association was absent in others
(von Kanel et al., 2010b, Sondergaard et al., 2004, McCanlies et al., 2011, von Kanel et al.,
2007, Sutherland et al., 2003, Vidovic et al., 2011, Baker et al., 2001). Other potential
inflammatory response markers, including fibrinogen (Robicsek et al., 2011, von Kanel et
al., 2006), white blood cell (WBC) count (Boscarino and Chang, 1999), and adhesion
molecules---including vascular cell adhesion molecule 1 (VCAM-1) and intercellular
adhesion molecule 1 (ICAM-1) (von Kanel et al., 2010a, von Kanel et al., 2008)---were
associated with PTSD in some previous studies, but not consistently. Also, few of these
studies (von Kanel et al., 2010b, von Kanel et al., 2006, von Kanel et al., 2008, Gill et al.,
2008) controlled for depression, and some did not adjust for any potential confounders
(Vidovic et al., 2011, Baker et al., 2001). In addition, it remains possible that observed
associations between inflammatory markers and PTSD are at least partially due to common
familial and genetic factors that influence both the inflammation response and PTSD. These
shared factors, which are potentially confounding but difficult to measure, can nonetheless
be controlled in twin analyses, since all twins share early maternal, familial, and
environmental factors, and monozygotic (MZ) twins share all genetic factors as well. Our
objective was to determine whether lifetime history of PTSD was associated with
inflammation. Further, we describe the confounding influence of familial and environmental
factors on the association between PTSD and inflammation.
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Methods
Study Population
The Emory Twin Studies include samples recruited in two companion studies: the Twins
Heart Study (THS) and the Stress and Vascular Evaluation in Twins (SAVEIT). The studies
were designed to explore psychological, in addition to behavioral and biologic, risk factors
for subclinical cardiovascular disease (Vaccarino et al., 2008a, Vaccarino et al., 2008b,
Rooks et al., 2012, Shah et al., 2011). For both studies, male monozygotic (MZ) and
dizygotic (DZ) twin pairs born between 1946 and 1956 were recruited from the Vietnam Era
Twin (VET) Registry (Goldberg et al., 2002). Identical study protocols were followed. The
sample (pooled across studies) included twin pairs where at least one member had PTSD or
depression, and control twin pairs with both members free of PTSD and depression. Our
sample included 562 twins or 281 twin pairs (170 monozygotic and 111 dizygotic pairs)
recruited and tested between 2002 and 2010. Of these, 86 individuals were excluded due to
previous cardiovascular disease history (coronary heart disease, myocardial infarction,
coronary artery bypass graft, percutaneous coronary angioplasty, cerebrovascular accident,
or peripheral vascular disease), leaving 476 individuals or 238 twin pairs. An additional 5–
30 individuals were excluded due to missing inflammatory marker information, resulting in
a final analysis sample between 446 and 471 individuals, depending on the inflammatory
biomarker. The number of complete pairs (both twins without previous history of
cardiovascular disease and with available inflammatory marker levels) ranged from 200 to
210.
Twin pairs were examined on the same date at the Emory University General Clinical
Research Center and medical history was obtained at the time of examination. The
institutional review board at Emory University approved the protocol, and informed consent
was obtained from all study participants.
Lifetime History of PTSD
A lifetime history of PTSD was based on a PTSD diagnosis from the Structured Clinical
Interview for DSM-IV (SCID) (First MB, 1995). The PTSD-specific module of the SCID
contains items assessing: (i) exposure to traumatic events (a major disaster, very serious
accident, or fire; being physically assaulted or raped; seeing another person killed or dead,
or badly hurt, or hearing about something horrible that has happened to someone you are
close to); (ii) reported nightmares, flashbacks, or persistent thoughts in response to the
(worst listed) traumatic event; (iii) emotional upset in situations that remind the participant
of the event; (iv) ≥1-month duration of these symptoms; and (v) clinically significant
distress or impairment in social, occupational, or other important areas of functioning due to
the disturbance. Following the PTSD diagnostic algorithm, PTSD is classified as either
current (met criteria in month prior to study visit) or past (did not meet criteria in month
prior to study visit), and both current and past diagnoses were included in the definition of
lifetime history of PTSD.
Inflammatory Markers
All inflammatory markers were measured in plasma from a single blood draw at the time of
study examination, and all biochemical assays for each twin pair were processed in the same
analytical run. Levels of high-sensitivity CRP (hsCRP) were measured with the high-
sensitivity Beckman Coulter assay (Beckman Coulter; Brea, CA). IL-6, VCAM-1, and
ICAM-1 were assessed using commercially available enzyme-linked immunosorbent assay
kits from R&D Systems (Minneapolis, MN). White blood cell count was measured with the
Beckman Coulter LH 750 hematology analyzer (Beckman Coulter Diagnostics), and
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fibrinogen was measured by using the Dade Behring BCS coagulation analyzer (Dade
Behring Inc., Newark, DE).
Potential Confounders
Potential confounding factors considered in this study included demographics (age),
behavioral factors (smoking, alcohol consumption, and physical activity), medications
(statins, aspirin), cardiovascular risk factors (hypertension, diabetes, BMI), and lifetime
history of depression, measured with the SCID. Physical activity was assessed by means of
the Baecke global physical activity score, which summarizes activity related to work, sports,
and leisure (Richardson et al., 1995). Smoking status and total alcohol consumption were
determined using standardized questionnaires from population studies (Howard et al., 1998,
Demirovic et al., 1993). Smoking status was categorized as current, past, and never
smoking. Total alcohol consumption (number of drinks within a typical week) included the
number of alcoholic (wine, beer, or cocktail) beverages consumed per week. Current
medication use was obtained by a trained research nurse during the study interview.
Diabetes was defined by a plasma fasting glucose of ≥126 mg/dl or the use of insulin or oral
hypoglycemic medications. Hypertension was defined by an average blood pressure ≥140/
≥90 mmHg (two measurements 5 minutes apart in seated position after 10 minutes of rest)
or the use of antihypertensive medications. Body mass index (BMI) was calculated as:
(weight in kg)/(height in m)2. The SCID provided a lifetime diagnosis of major depression.
Military service factors (Vietnam theater and combat exposure) were determined from
military records via the VET Registry. Zygosity information on the twin pairs was assessed
with DNA samples as described previously (Forsberg et al., 2010).
Statistical Analysis
Initial descriptive analyses were performed treating twins as individuals. Characteristics
were compared by lifetime history of PTSD using t and χ2 tests according to variable
distribution. The association between PTSD and each inflammatory marker was assessed at
the individual level, accounting for clustering by twin pair. All inflammatory markers were
log-transformed to normalize their right-skewed distributions and pairwise correlations were
assessed. The association between PTSD and inflammatory markers was analyzed using
mixed-model linear regression analyses modeling inflammatory markers (dependent
variables) and PTSD (independent variable), with a random intercept for each pair (Carlin et
al., 2005). Geometric mean levels and percent differences by PTSD were obtained from the
models. Analyses were conducted before and after sequentially adjusting for groups of
variables as described above. Additional analyses were performed to compare geometric
mean levels of inflammatory markers and perform tests for trend with PTSD classified into
three levels as current, past, or no PTSD. Results were further examined stratified by service
in the Vietnam theater to determine whether the associations of inflammatory marker levels
with PTSD differed by this exposure. Sensitivity analyses excluding potential outliers
(values >3 SD from the geometric mean) and defining depression as ordinal (none, past, and
current) were also performed.
Further models separately estimated the PTSD and inflammation associations within twin
pairs in complete twin pairs. Within-pair analyses control for shared but unmeasured
familial and antecedent environmental factors; when within-pair effects are smaller than the
effects seen when twins are analyzed as separate individuals, this points to confounding by
factors shared by twin pairs (Carlin et al., 2005). Due to power concerns with small numbers
of pairs, these models were adjusted for a smaller set of confounders (age, physical activity,
smoking, statins, and BMI), including those that were considered confounders by a priori
consideration or by being associated with the exposure (PTSD), as well as with the outcome
(P <0.10 in fully-adjusted individual-level models for at least two inflammatory markers).
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The within-pair analyses were also stratified by zygosity and interaction terms (zygosity ×
PTSD) were tested to determine whether the relationship between PTSD and inflammatory
markers was different between MZ and DZ twins, in whom genetic factors are accounted for
completely and partially, respectively. All within-pair analyses were performed in PTSD-
discordant pairs (in which one twin has PTSD and the co-twin does not). The association is
likely confounded by genetic factors if the within-pair effect is smaller in MZ than in DZ
twins (McGue et al., 2010). All statistical analyses were performed using SAS software
version 9.3 (SAS Institute, Cary, NC), and the statistical significance threshold was set at
two-sided α=0.05.
Results
Characteristics of twins
Overall, 12.4% (59/476) of the study population of twins without previous cardiovascular
disease history had a lifetime history of PTSD. Of the 59 twins with lifetime history of
PTSD, 25 had current PTSD while 34 had past PTSD. Discordant pairs, in which one twin
had PTSD and the other did not, comprised 17.7% of the pairs (42/238, 16.0% of DZ and
20.1% of MZ). The number of discordant pairs with complete information on both co-twins
for the inflammatory markers ranged from 29 to 33. There were only 10 pairs (4.2%) where
both co-twins had PTSD. Twins were predominantly white (96.2% of pairs). Other
characteristics of participating twins are shown in Table 1. Those with PTSD were older by
about 2 years, on average; however, other demographics, including educational attainment
and marital status did not differ by PTSD status. Those with a lifetime history of PTSD were
more likely to smoke and reported about twice as many alcoholic drinks per week, on
average, than those without PTSD. Those with PTSD were also more likely to have
hypertension and a lifetime history of depression and to have served in the Vietnam theater
and to have had exposure to combat than their PTSD-free counterparts. Pairwise correlations
between the inflammatory markers were generally weakly to moderately positive and
statistically significant (Supplemental Table 1), with the correlations between hsCRP and
fibrinogen (ρ=0.53), hsCRP and IL-6 (ρ=0.45), hsCRP and WBC count (ρ=0.41), and IL-6
and ICAM-1 (ρ=0.41) having the largest magnitude (all P<0.001).
Overall association of PTSD with inflammatory markers
Among twins treated as separate individuals, age-adjusted levels of hsCRP and ICAM-1
were significantly higher among twins with a history of PTSD compared to those without a
history of PTSD (Table 2), with the age-adjusted percent difference being 50.9% for hsCRP
and 11.4% for ICAM-1 (Figure 1). Additionally, those with PTSD tended to have lower age-
adjusted levels of IL-6 than their counterparts without PTSD (percent difference, −13.2%;
Figure 1), but the difference was not statistically significant. Of the remaining inflammatory
markers examined, none had a substantial or statistically significant difference in age-
adjusted levels by PTSD status (Table 2).
With full adjustment, the association of hsCRP with PTSD became less pronounced (percent
difference, 33.2%); inclusion of depression in the model attenuated the association between
PTSD and hsCRP (Table 2). ICAM-1, however, remained positively associated with PTSD
with a slightly lower percent difference with full adjustment (9.0%; Figure 1). In contrast,
lower levels of IL-6 were significantly associated with PTSD (−22.5% difference) in fully
adjusted models. Significant or marginally significant potential confounders in fully adjusted
models (including depression) included: smoking (positively associated with all
inflammatory markers), physical activity (negatively associated with hsCRP and fibrinogen),
statin use (negatively associated with hsCRP and ICAM-1), BMI (positively associated with
IL-6, fibrinogen, and WBC count), and age (negatively associated with IL-6 and ICAM-1).
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Sensitivity analyses excluding outliers showed nearly identical fully adjusted levels of
inflammatory markers for no PTSD vs. PTSD (data not shown). Similarly, sensitivity
analyses examining depression as an ordinal rather than dichotomous variable made no
difference in the fully adjusted levels of inflammatory markers comparing no PTSD to
PTSD (data not shown).
When we examined a three-level ordinal indicator of PTSD (current, past, and never), we
found a statistically significant increasing trend of association of PTSD with hsCRP, such
that those with current PTSD had higher levels of hsCRP than those with past PTSD, and
those with past PTSD had higher levels than those who had never had PTSD. These results
remained significant after adjusting for behavioral and cardiovascular risk factors and
depression (Table 3). In contrast, current and past PTSD showed similar levels of ICAM-1,
although levels in those with current and past PTSD were higher than those who never had
PTSD (Table 3). The ordinal PTSD measure was not associated with IL-6.
Finally, the age-adjusted geometric mean levels of all inflammatory markers by PTSD were
examined in models stratified by Vietnam theater service and combat exposure. The
associations with PTSD did not differ by Vietnam theater service or combat exposure, and
tests for interactions (Vietnam service × PTSD and combat exposure × PTSD) were non-
statistically significant for all markers.
Within-twin pair association of PTSD with inflammatory markers
When the twin pairs who were discordant for lifetime history of PTSD were analyzed
comparing each twin with PTSD to his brother without PTSD, the associations of most
markers with PTSD were generally similar in direction but smaller in magnitude, compared
to those seen in all twins (Table 4). hsCRP was not significantly associated with PTSD
among these discordant twins (Table 4). Only ICAM-1 was significantly and positively
associated with PTSD in the within-pair analysis, and the magnitude of this association did
not differ substantially from that found in the analysis of twins as individuals. None of the
remaining markers, including IL-6, were associated with PTSD in within-pair analyses.
Models that were stratified by zygosity (Supplemental Table 2) showed that, in general,
effects did not appear to differ in MZ and DZ twin pairs, and there was no evidence of
statistically significant zygosity-mediated effect modification for any of the inflammatory
markers, although sample sizes were small (12–19 pairs) for these analyses.
Discussion
We found that both hsCRP and ICAM-1 were higher among twins with PTSD than among
those without PTSD. hsCRP was particularly high in twins with current PTSD, with a
gradation of effects across levels of PTSD classified as never, past, or current PTSD.
Adjustment for depression rendered the association between PTSD and hsCRP less
statistically significant, although it remains unknown whether depression has a confounding
effect or is, in fact, in the causal pathway between PTSD and inflammation. Conversely, no
consistent association was found between PTSD and IL-6 in our analyses, and no
meaningful trend in IL-6 was observed across categories of never, past, or current PTSD.
There was no evidence of effect modification by Vietnam theater service for hsCRP, IL-6,
or ICAM-1. The remaining examined markers---fibrinogen, WBC count, and VCAM-1---
were not associated with PTSD.
When we examined the within-twin pair associations of PTSD with the inflammatory
markers, we found that these effects were smaller in magnitude than the overall effects for
most markers, with the exception of ICAM-1, providing evidence of familial confounding in
the associations of these inflammatory markers with PTSD. Since DZ twins, like any full
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siblings, share, on average, 50% of their genes, while MZ twins share 100% of their genes,
we would expect that the magnitude of the associations would be lessened among MZ
compared to DZ twins if genetic factors were confounders. However, zygosity-stratified
analyses showed no evidence of interaction for any of the markers and estimates were
generally similar or even higher among DZ than MZ twin pairs. Thus, it is likely that most
of the shared familial factors that confound the associations are not genetic in nature.
Of all the markers we examined, the association of hsCRP with PTSD had the largest
magnitude, with levels being about one-third higher in those with vs. without PTSD after
adjustment for several potential confounders, including depression. Accounting for both
measured confounders and unmeasured early-life shared factors, levels remained >11%
higher in those with PTSD. These results confirm previous data from a population-based
study in Germany, which found greater odds of elevated hsCRP among those with PTSD,
although this association was not adjusted for depression (Spitzer et al., 2010). Other
previous studies found that PTSD was associated with lower, rather than higher hsCRP
levels, or that hsCRP was not associated with PTSD at all (von Kanel et al., 2010b,
Sondergaard et al., 2004, Sutherland et al., 2003, McCanlies et al., 2011, von Kanel et al.,
2007). However, these studies tended to be small and none adjusted for a full array of
potential confounding factors.
We also found that IL-6 was negatively associated with lifetime history of PTSD, although
the result was not confirmed in within-twin pair analyses. Previous studies have been
inconsistent regarding an association between IL-6 and PTSD (von Kanel et al., 2010b,
Sutherland et al., 2003, Tucker et al., 2010, Gill et al., 2008, McCanlies et al., 2011, Vidovic
et al., 2011, Baker et al., 2001). One possible explanation may be related to the complex
biological properties of IL-6: IL-6 can activate the immune system but it also has anti-
inflammatory properties in the acute phase of the stress reaction (Scheller et al., 2011, Xing
et al., 1998). We observed that IL-6 tended to be lower in twins with past, but not current,
PTSD. Although the reasons for this association are unknown, the low levels of IL-6 may
reflect long-term suppression of the anti-inflammatory IL-6 response due to a hypersensitive
hypothalamus-pituitary-adrenal axis (Yehuda, 2002a). It may also be that those who recover
from PTSD, or who are exposed to a single traumatic event rather than multiple events
(Handwerger, 2009), are more resilient, and thus better able to counteract PTSD-related
immune dysfunction, than those who do not. Another possible explanation for these
inconsistencies is that men may be more likely to inhibit the pro-inflammatory response of
IL-6 than women (Rohleder et al., 2001). Four of six studies that included women (Gill et
al., 2008, von Kanel et al., 2010b, Sutherland et al., 2003, Tucker et al., 2010, McCanlies et
al., 2011, Vidovic et al., 2011, Baker et al., 2001) found a positive association of PTSD with
IL-6, whereas one prior study including only men (Vidovic et al., 2011) showed no
association. Clearly, this unexpected but potentially spurious finding needs to be confirmed
in other samples, and, if the finding is confirmed, the role of IL-6 in the neuroimmunology
of PTSD may need further clarification.
ICAM-1 is elevated in response to inflammatory cytokines and may directly contribute to
the atherosclerotic process over time via the binding of leukocytes to endothelial cells. We
found that, after adjustment for potential confounders and even after accounting for shared
early-life familial and environmental factors in within-twin pair analyses, levels of ICAM-1
were 9% higher among those with PTSD compared to their PTSD-free counterparts. To our
knowledge, this observed association was only reported once before (von Kanel et al.,
2010a), in a study of persons with PTSD secondary to myocardial infarction. Another study
by the same group (von Kanel et al., 2008), however, found no association of ICAM-1 with
PTSD, although the study was limited by its small size (14 cases and 14 controls).
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Fibrinogen, a coagulation factor that is also involved in the inflammation response, has thus
far shown no evidence of being associated with PTSD (Robicsek et al., 2011, von Kanel et
al., 2006), and our results confirmed this lack of association. In our study, WBC count and
VCAM-1 were also not associated with lifetime history of PTSD. Few previous studies have
examined these inflammatory biomarkers in relation to PTSD (Boscarino and Chang, 1999,
von Kanel et al., 2010a). While these studies reported significant associations, their results
are difficult to compare with ours due to differing etiologies and definitions of PTSD.
There are several study limitations worthy of mention. First, the cross-sectional design
precludes assessment of a temporal relationship between PTSD and subsequent
inflammation and also does not exclude the possibility that inflammation may lead to
increased susceptibility to PTSD. There is also the possibility of misclassification in both
PTSD and the inflammatory markers. A dichotomous diagnosis of PTSD may not capture
the severity, duration, and/or recency of PTSD symptoms, and, importantly, elevations of
inflammatory markers at a single time point may not represent chronic inflammation.
Furthermore, although we excluded individuals with extant CVD to minimize inflammation
due to active disease, we cannot be sure that individuals with subclinical CVD were not
included in the study. Also, our study population included only male middle-aged veterans
and the results may not be generalizable to female or to civilian populations of different age
groups. Sample sizes in within-twin analyses, particularly those stratified by zygosity, were
small, which limited our power to detect differences by PTSD and our ability to make
inferences regarding the influence of genetic and non-genetic familial factors. The small
sample sizes of PTSD-discordant twin pairs also precluded the examination of the ordinal
PTSD variable in the within-pairs analyses and, consequently, potential differential familiar
influences between past and current PTSD. Additionally, many of the inflammatory markers
were weakly to moderately positively correlated; thus, it is possible that the chosen alpha of
0.05 may be too high and that borderline statistically significant results should be interpreted
with caution. Finally, as with any observational study, there may be residual confounding;
however, the ability to control for confounding due to unknown familial factors is one of the
greatest strengths of our twin study design. Other strengths of our study include the
relatively large sample size for individual-level analysis, the examination of several
inflammatory biomarkers, and available data on a wide variety of potential confounders,
including lifetime history of depression. Additionally, our results suggesting that the effects
of PTSD may be independent of familial factors mirror those seen with twin studies of
PTSD and inflammatory conditions such as rheumatoid arthritis (Boscarino et al., 2010) and
asthma (Goodwin et al., 2007).
In conclusion, using an array of inflammatory biomarkers, we were able to discover that
individuals with PTSD, compared with those without, have elevated levels of hsCRP and
ICAM-1, while IL-6, fibrinogen, VCAM-1, and WBC are not similarly elevated in PTSD.
Inflammatory abnormalities in PTSD may be at least partially due to unknown familial,
possibly non-genetic, factors. Our results indicate that the link between PTSD and
inflammation is complex and is in part influenced by shared environmental substrates that
predispose individuals to both PTSD and alterations in inflammation.
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Figure 1.
Percent difference in mean value of inflammatory marker for twins with PTSD vs. without
PTSD, with twins treated as individuals. Values are plotted for age-adjusted and fully-
adjusted (including depression) differences by PTSD. P values can be found in Table 2.
hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; WBC, white blood cell;
ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1.
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Figure 2.
Within-twin pair percent difference in mean value of inflammatory marker in PTSD-
discordant pairs. Values are plotted for age-adjusted and fully-adjusted differences by
PTSD. P values can be found in Table 3. hsCRP, high-sensitivity C-reactive protein; IL-6,
interleukin 6; WBC, white blood cell; ICAM-1, intercellular adhesion molecule 1;
VCAM-1, vascular cell adhesion molecule 1.
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Table 1
Characteristics of Emory Twin Study participants, according to lifetime history of PTSD
Characteristic N No PTSD PTSD P*
Demographics
 Mean age (SD), years 476 55.1 (3.2) 57.4 (2.0) <0.001
 % married 466 98.1% 96.6% 0.358
 % high school graduate 476 72.4% 64.4% 0.202
Behaviors
 Mean no. of drinks per week (SD) 473 4.6 (8.4) 8.6 (12.8) 0.002
 Mean Baecke physical activity score (SD) 474 7.4 (1.7) 7.3 (1.9) 0.668
 % smoking 475 0.021
  % current smoking 21.2% 37.3%
  % past smoking 43.5% 32.2%
Medications
 % on aspirin 476 19.9% 20.3% 0.938
 % on statins 476 20.9% 15.3% 0.315
Cardiovascular risk factors
 Mean BMI 475 29.4 (4.9) 29.9 (4.4) 0.462
 % with diabetes 476 8.6% 8.5% 0.968
 % with hypertension 476 45.8% 64.4% 0.007
Psychiatric conditions
 % with history of depression 474 20.0% 54.2% <0.001
Military service
 % in Vietnam theater 476 39.6% 86.4% <0.001
 % with combat exposure 476 29.3% 86.4% <0.001
*
By t test (continuous variables) and χ2 or Fisher’s exact test (categorical variables).
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Table 3
Adjusted mean level of inflammatory markers, according to PTSD status (no PTSD, past PTSD, and current
PTSD).
Marker N
Mean (95% CI)
Age-Adjusted Fully Adjusted** Fully Adjusted***
hsCRP (mg/l) 471
 No PTSD 1.30 (1.14, 1.49) 1.31 (1.16, 1.48) 1.31 (1.16, 1.49)
 Past PTSD 1.53 (1.07, 2.19) 1.42 (1.01, 1.99) 1.40 (1.00, 1.98)
 Current PTSD 2.87 (1.86, 4.41) 2.47 (1.64, 3.71) 2.45 (1.61, 3.71)
 Ptrend <0.001 0.007 0.010
IL-6 (pg/ml) 468
 No PTSD 1.59 (1.47, 1.73) 1.61 (1.48, 1.74) 1.61 (1.49, 1.75)
 Past PTSD 1.24 (0.95, 1.63) 1.12 (0.85, 1.47) 1.11 (0.85, 1.47)
 Current PTSD 1.61 (1.17, 2.21) 1.48 (1.07, 2.03) 1.47 (1.06, 2.04)
 Ptrend 0.470 0.131 0.136
Fibrinogen (mg/dl) 445
 No PTSD 340 (331, 350) 341 (333, 350) 341 (333, 350)
 Past PTSD 331 (306, 358) 326 (302, 352) 323 (299, 349)
 Current PTSD 355 (324, 388) 348 (318, 380) 343 (313, 375)
 Ptrend 0.647 0.921 0.651
WBC (103/μ1) 446
 No PTSD 6.19 (6.01, 6.38) 6.21 (6.04, 6.38) 6.22 (6.05, 6.39)
 Past PTSD 6.21 (5.68, 6.8) 6.08 (5.59, 6.62) 6 (5.51, 6.53)
 Current PTSD 6.31 (5.71, 6.97) 6.21 (5.65, 6.84) 6.07 (5.51, 6.69)
 Ptrend 0.735 0.880 0.488
VCAM-1 (ng/ml) 470
 No PTSD 589 (567, 612) 588 (566, 611) 588 (566, 611)
 Past PTSD 601 (541, 669) 595 (537, 659) 601 (541, 667)
 Current PTSD 578 (509, 658) 595 (525, 675) 605 (533, 688)
 Ptrend 0.952 0.806 0.599
ICAM-1 (ng/ml) 470
 No PTSD 292 (283, 302) 293 (284, 302) 293 (284, 302)
 Past PTSD 325 (298, 354) 314 (288, 342) 317 (290, 345)
 Current PTSD 327 (294, 364) 320 (288, 355) 324 (292, 360)
 Ptrend 0.007 0.045 0.027
hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; WBC, white blood cell; ICAM-1, intercellular adhesion molecule 1; VCAM-1,
vascular cell adhesion molecule 1.
*Geometric means.
**Adjusted for age, physical activity, current smoking, alcohol intake, aspirin use, statin use, diabetes, hypertension, and body mass index.
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***Adjusted for age, physical activity, current smoking, alcohol intake, aspirin use, statin use, diabetes, hypertension, body mass index, and
lifetime history of depression.
Brain Behav Immun. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Plantinga et al. Page 18
Ta
bl
e 
4
M
ea
n*
 
le
ve
l o
f i
nf
la
m
m
at
or
y 
m
ar
ke
rs
, b
y 
PT
SD
 st
at
us
, w
ith
in
 tw
in
 p
ai
rs
 d
isc
or
da
nt
 fo
r P
TS
D
In
fla
m
m
at
or
y 
M
ar
ke
r
N
*
*
A
ge
-a
dju
ste
d
A
dju
ste
d*
*
*
M
ea
n,
 N
o 
PT
SD
 (9
5%
 C
I)
M
ea
n,
 P
TS
D
 (9
5%
 C
I)
P
M
ea
n,
 N
o 
PT
SD
 (9
5%
 C
I)
M
ea
n,
 P
TS
D
 (9
5%
 C
I)
P
hs
CR
P 
(m
g/l
)
33
1.
46
 (1
.01
–2
.11
)
1.
88
 (1
.30
–2
.72
)
0.
18
1.
58
 (1
.12
–2
.23
)
1.
76
 (1
.25
–2
.49
)
0.
55
IL
-6
 (p
g/m
l)
33
1.
27
 (0
.98
–1
.63
)
1.
29
 (1
.00
–1
.66
)
0.
89
1.
30
 (1
.02
–1
.66
)
1.
21
 (0
.95
–1
.54
)
0.
45
Fi
br
in
og
en
 (m
g/d
l)
29
33
5 
(30
5–
36
9)
34
7 
(30
5–
37
0)
0.
40
33
6 
(30
5–
37
0)
34
4 
(31
2–
37
9)
0.
48
W
BC
 (1
03
/μ1
)
29
6.
34
 (5
.71
–7
.04
)
6.
51
 (5
.86
–7
.23
)
0.
64
6.
57
 (6
.02
–7
.18
)
6.
23
 (5
.7–
6.8
1)
0.
29
V
CA
M
-1
 (n
g/m
l)
33
61
9 
(55
4–
69
3)
60
9 
(55
4–
69
1)
0.
67
61
9 
(55
4–
69
1)
58
8 
(52
7–
65
7)
0.
17
IC
A
M
-1
 (n
g/m
l)
33
27
1 
(24
4–
30
0)
30
5 
(24
8–
29
6)
0.
00
2
27
1 
(24
8–
29
6)
29
8 
(27
3–
32
5)
0.
00
5
hs
CR
P,
 h
ig
h-
se
ns
iti
vi
ty
 C
-re
ac
tiv
e 
pr
ot
ei
n;
 IL
-6
, i
nt
er
le
uk
in
 6
; W
BC
, w
hi
te
 b
lo
od
 ce
ll;
 IC
A
M
-1
, i
nt
er
ce
llu
la
r a
dh
es
io
n 
m
ol
ec
ul
e 1
; V
CA
M
-1
, v
as
cu
la
r c
el
l a
dh
es
io
n 
m
ol
ec
ul
e 1
.
*
G
eo
m
et
ric
 m
ea
ns
.
*
*
N
um
be
r o
f d
isc
or
da
nt
 tw
in
 p
ai
rs
.
*
*
*
A
dju
ste
d f
or 
ag
e, 
ph
ysi
cal
 ac
tiv
ity
, c
urr
en
t s
mo
kin
g, 
sta
tin
 us
e, 
an
d b
od
y m
ass
 in
de
x.
Brain Behav Immun. Author manuscript; available in PMC 2014 May 01.
